Rucaparib improves radiographic progression-free survival when compared with physician’s choice of therapy in patients with metastatic castration-resistant prostate cancer, according to results from the TRITON3 trial.
Adding talazoparib to first-line treatment with enzalutamide improves radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer, results of the TALAPRO-2 trial suggest.
AAP and apalutamide may improve outcomes, compared with bicalutamide, in a subgroup of patients with prostate cancer receiving ADT and salvage radiation after radical prostatectomy, according to researchers.
Adding olaparib to first-line treatment with abiraterone extends overall survival in patients with metastatic castration-resistant prostate cancer, a phase 3 study suggests.
In the era of immune checkpoint inhibitors, cytoreductive nephrectomy retains an important role in mRCC in carefully selected patients, according to investigators.
Possible reasons for the survival disparity include differences in obesity and smoking incidence among Black men younger than 50 years.
Patients with PD-L1 expression at initial transurethral resection for bladder cancer were more likely to harbor invasive disease, according to investigators.
Validation of the cytokine markers within the entire NIVOREN study is ongoing.
Neoadjuvant enfortumab vedotin demonstrated promising initial results in a small number of cisplatin-ineligible patients with muscle-invasive bladder cancer, according to investigators.
Early-salvage radiation therapy was associated with reduced risks for biochemical recurrence and metastasis, compared with expectant management.
Please login or register first to view this content.
